Tonix Expands Medicare Coverage for Fibromyalgia Treatment TONMYA
Tonix Pharmaceuticals has secured a new managed Medicare payer agreement to expand coverage for its fibromyalgia drug TONMYA, potentially reaching 9 million additional beneficiaries. Combined with existing agreements and Medicaid coverage, the treatment is expected to be available to approximately 145 million insured lives in the U.S., representing about 46% of total insured population.
Tickers: $TNXP
Topics: commercial_rollout drug_coverage medicare